Safety Profile of Rosuvastatin
- 1 January 2007
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 30 (2) , 157-170
Abstract
Background and objective:Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or ‘statins’, launched in the UK in March 2003. Our objective was...Keywords
This publication has 21 references indexed in Scilit:
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Do statins slow down Alzheimer's disease? A reviewJournal of Clinical Pharmacy and Therapeutics, 2004
- Rosuvastatin — warfarin drug interactionThe Lancet, 2004
- Autoimmune hepatitis revealed by atorvastatinEuropean Journal of Gastroenterology & Hepatology, 2003
- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ, 2003
- Statin-Associated Myopathy with Normal Creatine Kinase LevelsAnnals of Internal Medicine, 2002
- Results of a postal survey of the reasons for non‐response by doctors in a Prescription Event Monitoring study of drug safetyPharmacoepidemiology and Drug Safety, 2002
- Statins and myopathyThe Lancet, 2002
- Drug firm withdraws statin from the marketThe Lancet, 2001
- Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitorsTrends in Pharmacological Sciences, 1998